NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Clinical trials for NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for indian men with aggressive prostate cancer: darolutamide trial launches
Disease control Recruiting nowThis study tests darolutamide, a drug that blocks male hormones fueling prostate cancer, in Indian men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). All 50 participants will take darolutamide pills twice a day along with standard hormone therapy. Th…
Matched conditions: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE4 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could testosterone shots keep prostate cancer at bay?
Disease control Recruiting nowThis phase 2 trial tests whether giving testosterone injections (bipolar androgen therapy) can delay the time it takes for prostate cancer to spread in men whose cancer is progressing despite standard treatment. About 69 men with non-metastatic castrate-resistant prostate cancer …
Matched conditions: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Australian and New Zealand Urogenital and Prostate Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Prostate cancer drug darolutamide under safety watch in korea
Knowledge-focused Recruiting nowThis study monitors the safety and effectiveness of darolutamide (Nubeqa) in 600 Korean men with non-metastatic or metastatic hormone-sensitive prostate cancer. Participants receive the drug as part of their normal care and are followed for one year. Researchers track side effect…
Matched conditions: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Massive global registry launches to track prostate cancer care worldwide
Knowledge-focused Recruiting nowThis study is a large international registry that will follow at least 5,000 men with advanced prostate cancer for five years or more. Researchers will collect detailed information on treatments, side effects, and quality of life to see which approaches work best. The goal is to …
Matched conditions: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Prostate Cancer Clinical Trials Consortium • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
5,000 men with advanced prostate cancer to be tracked in new registry study
Knowledge-focused Recruiting nowThis study is a registry that will follow about 5,000 men with prostate cancer that has come back or spread. It aims to record which treatments doctors actually use in routine care and how the disease progresses over time. Participants are grouped by their cancer stage, from PSA …
Matched conditions: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: UroTrials Company (GmbH) • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC